U.S. markets close in 4 hours 36 minutes

Oragenics, Inc. (OGEN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.6840+0.0262 (+3.98%)
As of 11:23AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.6578
Open0.6580
Bid0.6801 x 800
Ask0.6880 x 1400
Day's Range0.6404 - 0.6860
52 Week Range0.3800 - 2.0900
Volume876,776
Avg. Volume12,605,577
Market Cap74.998M
Beta (5Y Monthly)0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.4680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • OGEN: COVID-19 Vaccine Candidate Exhibits Protective Immunity in Mice…
    Zacks Small Cap Research

    OGEN: COVID-19 Vaccine Candidate Exhibits Protective Immunity in Mice…

    By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update CoV-2 S-2P Demonstrates Protective Immunity in Mice In February 2021, Oragenics, Inc. (NYSE:OGEN) announced data from the National Institutes of Health (NIH) that demonstrated the stabilized prefusion spike protein CoV-2 S-2P (which is being developed as the COVID-19 vaccine Terra CoV-2) induced protective immunity

  • Benzinga

    Oragenics' COVID-19 Related Deal Pushes The Stock Higher

    Oragenics Inc (NYSE: OGEN) stock is soaring higher after announcing a deal related to its Terra CoV-2 vaccine candidate against COVID-19. Oragenics has reached an agreement with Biodextris that will allow it to use Biodextris' BDX100, BDX300, and BDX301 proteosome-based adjuvants in the Terra CoV-2 vaccine. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300, and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides with the benefits of intranasal vaccine administration. Oragenics plans to start with animal testing of the vaccine in combination with the adjuvants. The deal between Oragenics and Biodextris also allows for a potential expansion in the future. That includes use in a commercial vaccine if Terra CoV-2 gets approval from the FDA. Price Action: OGEN shares increased 38.5% at $1.17 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaWhy Is Graybug Vision Stock Plunging Today?Cyclo Therapeutics Receives Positive EMA Pediatric Committee Opinion For Trappsol Cyclo© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine
    Business Wire

    Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

    Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine